GlassScriptPhysician profile
Michael P Bagley
NPI 1790703486
$5,691.33
in general payments reported to CMS, 2019-2025
37 companies · $1,302 in 2025
The $1,302 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $226 · 2021: $576 · 2022: $990 · 2023: $815 · 2024: $1,038 · 2025: $1,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,154.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $760.19 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $529.67 | 2020-2025 | Otezla, Otezla |
| Leo Pharma INC. | $499.56 | 2019-2025 | Adbry, Anzupgo |
| Mayne Pharma Commercial LLC | $424.67 | 2019-2025 | |
| Janssen Biotech, INC. | $328.33 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $321.85 | 2019-2025 | |
| Lilly USA, LLC | $306.76 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $300.02 | 2021-2025 | Opzelura |
| Pfizer INC. | $290.30 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $255.95 | 2019-2024 | Cabtreo, Jublia, Arazlo |
| Sun Pharmaceutical Industries INC. | $234.59 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Galderma Laboratories, L.P. | $207.87 | 2019-2025 | Aklief, Nemluvio |
| Dermavant Sciences, INC. | $201.06 | 2023-2024 | Vtama |
| Ucb, INC. | $105.91 | 2021-2024 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $90.13 | 2022-2025 | Sotyktu |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $87.47 | 2021-2023 | |
| Arcutis Biotherapeutics, INC. | $84.98 | 2024-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $69.38 | 2021-2025 | Dupixent, Libtayo |
| Epi Health, LLC | $51.61 | 2021 | |
| Journey Medical Corporation | $49.69 | 2022-2024 | |
| Organon LLC | $47.34 | 2025 | Vtama |
| Almirall LLC | $42.90 | 2022-2025 | Klisyri |
| Dermira, INC. | $42.60 | 2019-2021 | |
| Sebela Pharmaceuticals INC. | $41.67 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $38.20 | 2021 | |
| Biofrontera INC. | $37.46 | 2019-2020 | |
| Botanix Sb INC | $36.77 | 2025 | Sofdra |
| Celgene Corporation | $36.47 | 2024 | Sotyktu |
| Sandoz INC. | $35.13 | 2020 | |
| Strata Skin Sciences, INC. | $24.16 | 2019 | |
| Mallinckrodt Hospital Products INC. | $21.22 | 2025 | Acthar |
| Convatec INC. | $21.18 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $14.47 | 2019 | |
| Lnhc, INC | $13.76 | 2025 | Zelsuvmi |
| Aclaris Therapeutics, INC. | $13.53 | 2019 | |
| Merck Sharp & Dohme LLC | $12.36 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bagley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.